Does the media refer more to ABUS or SION?

In the previous week, Sionna Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Sionna Therapeutics and 4 mentions for Arbutus Biopharma. Sionna Therapeutics' average media sentiment score of 0.56 beat Arbutus Biopharma's score of 0.52 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arbutus Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, SION or JBIO?

Jade Biosciences is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A Jade Biosciences N/A N/A -$127.41M -$1.92 N/A

Is SION or JBIO more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Jade Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Jade Biosciences N/A -49.11% -45.62%

Does the media prefer SION or JBIO?

In the previous week, Sionna Therapeutics had 3 more articles in the media than Jade Biosciences. MarketBeat recorded 5 mentions for Sionna Therapeutics and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.61 beat Sionna Therapeutics' score of 0.56 indicating that Jade Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Jade Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer RIGL or SION?

In the previous week, Sionna Therapeutics had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for Sionna Therapeutics and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.89 beat Sionna Therapeutics' score of 0.56 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rigel Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, SION or SANA?

Sana Biotechnology is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sionna Therapeutics N/A N/A -$75.27M -$2.18 N/A Sana Biotechnology N/A N/A -$244.17M -$0.76 N/A

Is SION or SANA more profitable?

Sionna Therapeutics' return on equity of -32.94% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sionna Therapeutics N/A -32.94% -31.08% Sana Biotechnology N/A -103.02% -39.16%

Does the media favor SION or SANA?

In the previous week, Sionna Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Sionna Therapeutics and 3 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.08 beat Sionna Therapeutics' score of 0.56 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sana Biotechnology 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or SION?

In the previous week, Sionna Therapeutics had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Sionna Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.61 beat Sionna Therapeutics' score of 0.56 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sionna Therapeutics (SION) Competitors

$4.90 0.00 (0.00%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$4.80 -0.11 (-2.14%)

As of 10/9/2026 07:54 PM Eastern

Compare

SION vs. ABUS, JBIO, RIGL, SANA, and LXRX

Should you buy Sionna Therapeutics stock or one of its competitors? Sionna Therapeutics's main competitors and comparable companies include Arbutus Biopharma (ABUS), Jade Biosciences (JBIO), Rigel Pharmaceuticals (RIGL), Sana Biotechnology (SANA), and Lexicon Pharmaceuticals (LXRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sionna Therapeutics compare to Arbutus Biopharma?

Arbutus Biopharma (NASDAQ:ABUS) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Arbutus Biopharma presently has a consensus price target of $5.00, indicating a potential upside of 18.48%. Sionna Therapeutics has a consensus price target of $42.33, indicating a potential upside of 763.95%. Given Sionna Therapeutics' higher possible upside, analysts clearly believe Sionna Therapeutics is more favorable than Arbutus Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arbutus Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Arbutus Biopharma has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Arbutus Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arbutus Biopharma	$14.08M	59.38	-$33.50M	$0.79	5.34
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

In the previous week, Sionna Therapeutics had 1 more articles in the media than Arbutus Biopharma. MarketBeat recorded 5 mentions for Sionna Therapeutics and 4 mentions for Arbutus Biopharma. Sionna Therapeutics' average media sentiment score of 0.56 beat Arbutus Biopharma's score of 0.52 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arbutus Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arbutus Biopharma has a beta of 0.76, meaning that its stock price is 24% less volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

43.8% of Arbutus Biopharma shares are held by institutional investors. 19.9% of Arbutus Biopharma shares are held by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arbutus Biopharma has a net margin of 84.22% compared to Sionna Therapeutics' net margin of 0.00%. Arbutus Biopharma's return on equity of 90.98% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arbutus Biopharma	84.22%	90.98%	82.34%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Summary

Arbutus Biopharma beats Sionna Therapeutics on 10 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Jade Biosciences?

Sionna Therapeutics (NASDAQ:SION) and Jade Biosciences (NASDAQ:JBIO) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Sionna Therapeutics' return on equity of -32.94% beat Jade Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Jade Biosciences	N/A	-49.11%	-45.62%

Sionna Therapeutics presently has a consensus target price of $42.33, indicating a potential upside of 763.95%. Jade Biosciences has a consensus target price of $51.75, indicating a potential upside of 259.62%. Given Sionna Therapeutics' higher possible upside, equities analysts clearly believe Sionna Therapeutics is more favorable than Jade Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jade Biosciences	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	2.90

Jade Biosciences is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Jade Biosciences	N/A	N/A	-$127.41M	-$1.92	N/A

In the previous week, Sionna Therapeutics had 3 more articles in the media than Jade Biosciences. MarketBeat recorded 5 mentions for Sionna Therapeutics and 2 mentions for Jade Biosciences. Jade Biosciences' average media sentiment score of 0.61 beat Sionna Therapeutics' score of 0.56 indicating that Jade Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Jade Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sionna Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Jade Biosciences has a beta of 1.64, suggesting that its stock price is 64% more volatile than the broader market.

Summary

Sionna Therapeutics and Jade Biosciences tied by winning 6 of the 12 factors compared between the two stocks.

How does Sionna Therapeutics compare to Rigel Pharmaceuticals?

Rigel Pharmaceuticals (NASDAQ:RIGL) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation, media sentiment and dividends.

66.2% of Rigel Pharmaceuticals shares are owned by institutional investors. 10.5% of Rigel Pharmaceuticals shares are owned by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Rigel Pharmaceuticals has higher revenue and earnings than Sionna Therapeutics. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Rigel Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rigel Pharmaceuticals	$294.28M	3.09	$367.02M	$16.32	3.01
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

In the previous week, Sionna Therapeutics had 3 more articles in the media than Rigel Pharmaceuticals. MarketBeat recorded 5 mentions for Sionna Therapeutics and 2 mentions for Rigel Pharmaceuticals. Rigel Pharmaceuticals' average media sentiment score of 0.89 beat Sionna Therapeutics' score of 0.56 indicating that Rigel Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Rigel Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Rigel Pharmaceuticals has a beta of 1.19, meaning that its stock price is 19% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.

Rigel Pharmaceuticals has a net margin of 116.30% compared to Sionna Therapeutics' net margin of 0.00%. Rigel Pharmaceuticals' return on equity of 22.95% beat Sionna Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rigel Pharmaceuticals	116.30%	22.95%	17.19%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Rigel Pharmaceuticals currently has a consensus target price of $59.00, suggesting a potential upside of 20.21%. Sionna Therapeutics has a consensus target price of $42.33, suggesting a potential upside of 763.95%. Given Sionna Therapeutics' higher probable upside, analysts clearly believe Sionna Therapeutics is more favorable than Rigel Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rigel Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Rigel Pharmaceuticals beats Sionna Therapeutics on 13 of the 15 factors compared between the two stocks.

How does Sionna Therapeutics compare to Sana Biotechnology?

Sionna Therapeutics (NASDAQ:SION) and Sana Biotechnology (NASDAQ:SANA) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, earnings, profitability, dividends, analyst recommendations, valuation, media sentiment and institutional ownership.

88.2% of Sana Biotechnology shares are owned by institutional investors. 5.1% of Sionna Therapeutics shares are owned by company insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Sionna Therapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 5 mentions for Sionna Therapeutics and 3 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.08 beat Sionna Therapeutics' score of 0.56 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sana Biotechnology	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A

Sionna Therapeutics currently has a consensus price target of $42.33, indicating a potential upside of 763.95%. Sana Biotechnology has a consensus price target of $9.33, indicating a potential upside of 234.53%. Given Sionna Therapeutics' higher possible upside, analysts clearly believe Sionna Therapeutics is more favorable than Sana Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

Sionna Therapeutics has a beta of 1, meaning that its stock price has a similar volatility profile to the broader market.Comparatively, Sana Biotechnology has a beta of 2.18, meaning that its stock price is 118% more volatile than the broader market.

Sionna Therapeutics' return on equity of -32.94% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sionna Therapeutics	N/A	-32.94%	-31.08%
Sana Biotechnology	N/A	-103.02%	-39.16%

Summary

Sana Biotechnology beats Sionna Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Sionna Therapeutics compare to Lexicon Pharmaceuticals?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Sionna Therapeutics (NASDAQ:SION) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, institutional ownership, analyst recommendations, risk, valuation, media sentiment, dividends and profitability.

Lexicon Pharmaceuticals has higher revenue and earnings than Sionna Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Sionna Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	15.01	-$50.34M	-$0.15	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$2.18	N/A

In the previous week, Sionna Therapeutics had 2 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 5 mentions for Sionna Therapeutics and 3 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 0.61 beat Sionna Therapeutics' score of 0.56 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Lexicon Pharmaceuticals currently has a consensus target price of $5.70, indicating a potential upside of 239.29%. Sionna Therapeutics has a consensus target price of $42.33, indicating a potential upside of 763.95%. Given Sionna Therapeutics' higher possible upside, analysts plainly believe Sionna Therapeutics is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sionna Therapeutics	1 Sell rating(s)	11 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexicon Pharmaceuticals has a beta of 1.07, suggesting that its stock price is 7% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.

Sionna Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Sionna Therapeutics' return on equity of -32.94% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Sionna Therapeutics	N/A	-32.94%	-31.08%

Summary

Lexicon Pharmaceuticals beats Sionna Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Sionna Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SION and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SION vs. The Competition

Export

Metric	Sionna Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$221.54M	$3.93B	$7.25B	$13.30B
Dividend Yield	N/A	3.64%	2.52%	22.58%
P/E Ratio	-2.25	13.55	275.01	26.14
Price / Sales	N/A	1,209.42	582.85	87.88
Price / Cash	N/A	119.49	76.96	53.71
Price / Book	0.71	17.17	11.22	6.33
Net Income	-$75.27M	-$22.69M	$3.50B	$382.15M
7 Day Performance	-0.20%	-1.34%	-0.89%	-1.40%
1 Month Performance	-37.58%	-8.04%	-4.02%	-3.35%
1 Year Performance	-83.34%	14.18%	7.13%	1.49%

Sionna Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SION Sionna Therapeutics	3.0878 of 5 stars	$4.90 flat	$42.33 +763.9%	-83.3%	$221.54M	N/A	N/A	59
ABUS Arbutus Biopharma	2.0984 of 5 stars	$4.56 -4.6%	$5.00 +9.6%	+2.7%	$946.95M	$14.08M	5.77	19	Short Interest Increase High Trading Volume
JBIO Jade Biosciences	1.8452 of 5 stars	$13.77 -2.0%	$51.75 +275.8%	+58.5%	$893.54M	N/A	N/A	55
RIGL Rigel Pharmaceuticals	4.2957 of 5 stars	$46.97 -2.5%	$59.00 +25.6%	+74.2%	$890.88M	$294.28M	2.88	174	Analyst Upgrade
SANA Sana Biotechnology	3.5202 of 5 stars	$2.89 -0.7%	$9.33 +223.0%	-35.4%	$872.64M	N/A	N/A	142	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SION) was last updated on 10/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sionna Therapeutics (SION) Competitors

SION vs. ABUS, JBIO, RIGL, SANA, and LXRX

How does Sionna Therapeutics compare to Arbutus Biopharma?

Summary

How does Sionna Therapeutics compare to Jade Biosciences?

Summary

How does Sionna Therapeutics compare to Rigel Pharmaceuticals?

Summary

How does Sionna Therapeutics compare to Sana Biotechnology?

Summary

How does Sionna Therapeutics compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sionna Therapeutics (SION) Competitors

SION vs. ABUS, JBIO, RIGL, SANA, and LXRX

How does Sionna Therapeutics compare to Arbutus Biopharma?

Do analysts rate ABUS or SION?

Which has higher valuation & earnings, ABUS or SION?

Does the media refer more to ABUS or SION?

Which has more risk & volatility, ABUS or SION?

Do institutionals & insiders believe in ABUS or SION?

Is ABUS or SION more profitable?

Summary

How does Sionna Therapeutics compare to Jade Biosciences?

Is SION or JBIO more profitable?

Do analysts rate SION or JBIO?

Which has better earnings and valuation, SION or JBIO?

Does the media prefer SION or JBIO?

Which has more volatility and risk, SION or JBIO?

Summary

How does Sionna Therapeutics compare to Rigel Pharmaceuticals?

Do institutionals and insiders hold more shares of RIGL or SION?

Which has better earnings & valuation, RIGL or SION?

Does the media prefer RIGL or SION?

Which has more risk & volatility, RIGL or SION?

Is RIGL or SION more profitable?

Do analysts rate RIGL or SION?

Summary

How does Sionna Therapeutics compare to Sana Biotechnology?

Do insiders & institutionals have more ownership in SION or SANA?

Does the media favor SION or SANA?

Which has better valuation and earnings, SION or SANA?

Do analysts prefer SION or SANA?

Which has more risk and volatility, SION or SANA?

Is SION or SANA more profitable?

Summary

How does Sionna Therapeutics compare to Lexicon Pharmaceuticals?

Which has better valuation and earnings, LXRX or SION?

Does the media prefer LXRX or SION?

Do insiders and institutionals believe in LXRX or SION?

Do analysts prefer LXRX or SION?

Which has more volatility and risk, LXRX or SION?

Is LXRX or SION more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SION vs. The Competition

Sionna Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools